BSX
Boston ScientificPrevious close
41.98
Change
−0.71 / −1.66%
P/E (TTM) ?
16.8
Market Cap
$61.1B
1M
−3.83%
S&P 500 −0.91% over same period
Volume / Avg Volume
22.5M / 22.1M
1.02× average
Latest earnings analysisFY2026 Q2Reported 2026-07-29
Boston Scientific Q2 FY2026: sales up 7.5%, adjusted EPS $0.86
Boston Scientific beat its own guidance in Q2 FY2026: sales of $5.442 billion, gross margin of 70.7% and adjusted EPS of $0.86, about two cents above the $0.8354 consensus estimate. The offset is the outlook — management guides third-quarter growth of 3 to 5 percent, below the 7.5 percent just delivered. That split is why the verdict here is Neutral. Below, we separate what actually happened from what management now expects.
Read the full analysis →Revenue$5.44BYoY +7.50%
EPS (non-GAAP)$0.86Beatest. $0.84
Next-day move−0.09%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-29 | $5.4B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-22 | $5.2B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-02-04 | $20.1B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-22 | $5.1B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-23 | $5.1B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-04-23 | $4.7B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 0 of its 5-year rangeCheap
5-year range 18.2 – 86.8 · Median 64.7
No buybacks or dividends in the last four quarters
P/E (TTM)
16.8
P/B
2.5
P/S
3.0
PEG
0.68
Earnings Reaction
Over the last 6 reports, the stock moved ±1.5% on average on the first trading day after, rising 3 times
Most recent −0.09%
Volatility & Correlation
1-year beta 0.14 · Correlation with S&P 500 0.05Low beta
Annualized volatility 39% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 6 · $9.5MSell 0 · $0.00MNet buying $9.5M
- 08-25Morano Susan EDirectorBuy$0.10M2,040 shares · Avg price 49.22
- 08-05Habiger David CDirectorBuy$0.10M2,100 shares · Avg price 47.59
- 08-04Habiger David CDirectorBuy$0.01M140 shares · Avg price 48.59
- 08-03Mahoney Michael FChairman, President & CEOBuy$9.0M186,240 shares · Avg price 48.33
- 08-03Habiger David CDirectorBuy$0.05M1,042 shares · Avg price 48.07
- 07-31LUDWIG EDWARD JDirectorBuy$0.23M5,000 shares · Avg price 45.48
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 5.44 | +7.5% | 70.7% | — | 0.61 |
| FY2026 Q1 | 5.20 | +11.6% | 69.4% | — | 0.90 |
| FY2025 Q4 | 5.29 | +15.8% | 69.6% | — | 0.45 |
| FY2025 Q3 | 5.07 | +20.3% | 69.9% | — | 0.51 |
| FY2025 Q2 | 5.06 | +22.8% | 67.7% | — | 0.53 |
| FY2025 Q1 | 4.66 | +20.9% | 68.8% | — | 0.45 |
| FY2024 Q4 | 4.56 | +22.5% | 67.9% | — | 0.38 |
| FY2024 Q3 | 4.21 | +19.3% | 68.8% | — | 0.32 |
| FY2024 Q2 | 4.12 | +14.5% | 69.2% | — | 0.22 |
| FY2024 Q1 | 3.86 | +13.8% | 68.6% | — | 0.33 |
| FY2023 Q4 | 3.73 | +14.9% | 69.2% | — | 0.34 |
| FY2023 Q3 | 3.53 | +11.3% | 68.8% | — | 0.34 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| BSX | 16.8 | +7.5% | 70.7% | −3.83% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |